CHAMPIONS ONCOLOGY, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for the quarter ending 2025-04-30 was $0.00.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for the quarter ending 2025-01-31 was $0.00.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for the quarter ending 2024-10-31 was $0.00, a 100.00% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for the quarter ending 2024-07-31 was $0.00, a 100.00% decline year-over-year.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for fiscal 2024 was $634.00K, a 756.76% increase from fiscal 2023.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for fiscal 2023 was $74.00K.
- CHAMPIONS ONCOLOGY, INC. payments for repurchase of common stock for fiscal 2022 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2025-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $0.00 10-K · filed 2025-07-23 |
| 2025-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | $0.00 derived: sum of 4 quarters · filed 2025-07-23 |
| 2024-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-16 | $0.00 derived: sum of 4 quarters · filed 2025-07-23 |
| 2024-07-31 | $0.00 10-Q · filed 2024-09-13 | $32.00K derived: sum of 4 quarters · filed 2025-07-23 |
| 2024-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-07-23 | $634.00K 10-K · filed 2025-07-23 |
| 2024-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | $708.00K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | $32.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-16 | $708.00K derived: sum of 4 quarters · filed 2024-12-16 |
| 2023-07-31 | $602.00K 10-Q · filed 2024-09-13 | $676.00K derived: sum of 4 quarters · filed 2024-09-13 |
| 2023-04-30 | $74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-19 | $74.00K 10-K · filed 2024-07-19 |
| 2023-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-15 | |
| 2022-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-13 | |
| 2022-07-31 | $0.00 10-Q · filed 2023-09-13 | |
| 2022-04-30 | $0.00 10-K · filed 2023-07-24 | |
| 2012-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-18 | $0.00 10-K · filed 2012-07-18 |
| 2012-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-03-14 | $960.00K derived: sum of 4 quarters · filed 2012-07-18 |
| 2011-10-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2011-12-14 | $960.00K derived: sum of 4 quarters · filed 2012-07-18 |
| 2011-07-31 | $0.00 10-Q · filed 2011-09-13 | $1.00M derived: sum of 4 quarters · filed 2012-07-18 |
| 2011-04-30 | $960.00K derived: 10-K 12 month − 10-Q 9 month · filed 2012-07-18 | $1.03M 10-K · filed 2012-07-18 |
| 2011-01-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2012-03-14 | |
| 2010-10-31 | $42.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2011-12-14 | |
| 2010-07-31 | $31.00K 10-Q · filed 2011-09-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |